The vectored intranasal delivery platform gives us the capability for rapid product development, scale-up, easy and painless immunization during public health emergencies and pandemics
China has the highest number of clinical trials that were initiated in NAFLD in the APAC region over the past decade.
Advent will also be making an open offer to acquire additional 26% of the outstanding equity shares of the company from the public shareholders.
Surana is a chartered accountant with an all-India rank.
First PARP inhibitor and new hormonal agent combination approved for these patients in Europe
The scheme is subject to statutory and regulatory approvals as may be necessary.
Subscribe To Our Newsletter & Stay Updated